RecruitingPHASE1, PHASE2NCT05230459
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Studying Calpain-3-related limb-girdle muscular dystrophy R1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AskBio Inc
- Intervention
- AB-1003 dose level 1(genetic)
- Enrollment
- 10 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2032
Study locations (6)
- University of California - Irvine, Irvine, California, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- VCU, Richmond, Virginia, United States
- University of Washington Medical Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05230459 on ClinicalTrials.govOther trials for Calpain-3-related limb-girdle muscular dystrophy R1
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05618080LGMD R1 Natural History StudyVirginia Commonwealth University
- ENROLLING BY INVITATIONNCT04989751A Multicenter Phenotype-Genotype Analysis of LGMD Patients in ChinaHuashan Hospital
See all trials for Calpain-3-related limb-girdle muscular dystrophy R1 →